Table 3.
Pharmacological treatment at the first prescription of a LAMA or a LABA/LAMA and after a 12-month follow-up
| Patients starting on LAMA | Patients starting on LABA/LAMA | ||||||
|---|---|---|---|---|---|---|---|
| N = 524 | N = 524 | ||||||
| Beginning | End (12 month) | Change % | Beginning | End (12 month) | Change % | Differences between groups (change LAMA—change LABA/LAMA) (CI) | |
| (End-beginning)(CI) | (End-beginning) (CI) | ||||||
| Treatment by drug | |||||||
| SABA | 92 (17.6) | 68 (13) | −4.6 (−8.9; −0.2)* | 98 (18.7) | 77 (14.7) | −4 (−8.5; 0.5) | −0.6 (−3; 1.9) |
| SAMA | 47 (9) | 34 (6.5) | −2.5 (−5.7; 0.7) | 54 (10.3) | 38 (7.3) | −3.1 (−6.5; 0.4) | 0.6 (−1.4; 2.6) |
| LABA | 0 | 27 (5.2) | 5.2 (3.3; 7)*** | 196 (37.4) | 117 (22.3) | −15.1 (−20.5; −9.6)*** | 20.2 (16.6; 23.8)*** |
| LAMA | 524 (100) | 439 (83.8) | −16.2 (−19.4; −13.1)*** | 184 (35.1) | 140 (26.7) | −8.4 (−14; −2.8)** | −7.8 (−11.8; −3.9)*** |
| SABA + SAMA | 0 | 0 | 0 (0; 0) | 0 | 1 (0.2) | 0.2 (−0.2; 0.6) | −0.2 (−0.6; 0.2) |
| LABA + LAMA | 0 | 22 (4.2) | 4.2 (2.5; 5.9)*** | 343 (65.5) | 282 (53.8) | −11.6 (−17.5; −5.7)*** | 15.8 (12.6; 19.1)*** |
| LABA + ICS | 0 | 49 (9.4) | 9.4 (6.9; 11.8)*** | 0 | 41 (7.8) | 7.8 (5.5; 10.1)*** | 1.5 (−1.9; 4.9) |
| ICS | 0 | 14 (2.7) | 2.7 (1.3; 4.1)*** | 0 | 25 (4.8) | 4.8 (2.9; 6.6)*** | −2.1 (−4.4; 0.2) |
| Methylxanthines | 1 (0.2) | 1 (0.2) | 0 (−0.5; 0.5) | 2 (0.4) | 1 (0.2) | −0.2 (−0.8; 0.5) | 0.2 (−0.2; 0.6) |
| IPDE4 | 0 | 0 | 0 (0; 0) | 1 (0.2) | 1 (0.2) | 0 (−0.5; 0.5) | 0 (0; 0) |
SABA short-acting beta-2 agonist, SAMA short-acting anti-muscarinic, LABA long-acting beta-2 agonist, LAMA long-acting anti-muscarinic, ICS inhaled corticosteroid, PDE4 phosphodiesterase 4 inhibitor
*p < 0.05; **p < 0.01; ***p < 0.001